Jean-Francois Millau

Company: TATUM Bioscience

Job title: CEO & Co-founder

Seminars:

Nanofilament-Directed Immunotherapy Ignites Robust Antitumor Vaccine Responses & Overcomes Neoantigen Prediction Bottlenecks 2:00 pm

• Bioengineered nanofilaments bypass the need to map individual neoantigens by directly converting cancer cells into targets for the immune system • Nanofilament biologic activities orchestrate the immune response – from tumor antigen capture to T-cell activation • Nanofilament-Directed Immunotherapy offers an off-the-shelf solution to ignite a robust antitumor vaccine response against the patient’s complete…Read more

day: Conference Day One